Aprea Therapeutics, Inc. filed a Form 8-K on November 20, 2026, disclosing updated results from its ongoing Phase 1 ACESOT-1051 trial of APR-1051 and a refreshed corporate presentation.
Key Highlights
- Trial update announced: Aprea Therapeutics issued a press release on November 20, 2026, reporting updated results from its ongoing Phase 1 ACESOT-1051 trial.
- Investigational compound: APR-1051 is described in the filing as "an investigational, oral, selective WEE1 inhibitor."
- Corporate presentation updated: The company also filed an updated corporate presentation slide deck dated November 2026 as Exhibit 99.2.
- Signed by CEO: The filing was signed by Oren Gilad, Ph.D., President and Chief Executive Officer, on November 20, 2026.
- Exchange listing: Common stock is registered on NASDAQ:APRE with a par value of $0.001 per share.
Aprea Therapeutics Discloses Phase 1 ACESOT-1051 Trial Results for WEE1 Inhibitor APR-1051
Aprea Therapeutics, Inc. (NASDAQ:APRE) filed a current report under Item 8.01 (Other Events) on November 20, 2026, disclosing that the company had issued a press release on the same date announcing updated results from its ongoing Phase 1 ACESOT-1051 clinical trial. According to the filing, APR-1051 is characterized as "an investigational, oral, selective WEE1 inhibitor." The press release was attached as Exhibit 99.1 and incorporated by reference into the filing.
In addition to the trial update, the filing states that Aprea Therapeutics updated its corporate presentation slide deck on November 20, 2026. That document was filed as Exhibit 99.2 and is likewise incorporated by reference. The filing does not include specific clinical data, efficacy figures, or safety summaries within the body of the 8-K itself; those details are contained in the referenced exhibits.
The report was signed by Oren Gilad, Ph.D., in his capacity as President and Chief Executive Officer of Aprea Therapeutics, Inc., a Delaware-incorporated company headquartered at 3805 Old Easton Road, Doylestown, PA 18902. The filing does not contain forward-looking statements within the 8-K body, though the company's press release and corporate presentation, incorporated by reference, may contain such statements subject to the company's cautionary language.
What Was Disclosed
Aprea Therapeutics filed an 8-K on November 20, 2026, to report updated Phase 1 ACESOT-1051 trial results for APR-1051, its investigational oral WEE1 inhibitor, and to file an updated corporate presentation, both incorporated by reference as exhibits.



Please wait processing your request...